Viamet Gets $60M In Private Financing After Nixing IPO
Antifungal drugmaker Viamet Pharmaceuticals on Monday scrapped its plans for a $75 million initial public offering and instead opted to raise $60 million in private venture financing and spin off its...To view the full article, register now.
Already a subscriber? Click here to view full article